135 related articles for article (PubMed ID: 10380709)
41. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy.
Murata K; Dalakas MC
Brain; 2000 Aug; 123 ( Pt 8)():1660-6. PubMed ID: 10908195
[TBL] [Abstract][Full Text] [Related]
42. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28.
Srinivasan M; Gienapp IE; Stuckman SS; Rogers CJ; Jewell SD; Kaumaya PT; Whitacre CC
J Immunol; 2002 Aug; 169(4):2180-8. PubMed ID: 12165548
[TBL] [Abstract][Full Text] [Related]
43. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
[TBL] [Abstract][Full Text] [Related]
44. Fine mapping of an IgE-controlling gene on chromosome 2q: Analysis of CTLA4 and CD28.
Howard TD; Postma DS; Hawkins GA; Koppelman GH; Zheng SL; Wysong AK; Xu J; Meyers DA; Bleecker ER
J Allergy Clin Immunol; 2002 Nov; 110(5):743-51. PubMed ID: 12417883
[TBL] [Abstract][Full Text] [Related]
45. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
46. CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley PS; Brady W; Urnes M; Grosmaire LS; Damle NK; Ledbetter JA
J Exp Med; 1991 Sep; 174(3):561-9. PubMed ID: 1714933
[TBL] [Abstract][Full Text] [Related]
47. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
48. Molecular mechanisms of costimulation.
Gilman SC; Noelle RJ
Agents Actions Suppl; 1998; 49():15-6. PubMed ID: 9426823
[No Abstract] [Full Text] [Related]
49. CD28-independent costimulation of T cells in alloimmune responses.
Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
[TBL] [Abstract][Full Text] [Related]
50. The CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders.
Naluai AT; Nilsson S; Samuelsson L; Gudjónsdóttir AH; Ascher H; Ek J; Hallberg B; Kristiansson B; Martinsson T; Nerman O; Sollid LM; Wahlström J
Tissue Antigens; 2000 Oct; 56(4):350-5. PubMed ID: 11098935
[TBL] [Abstract][Full Text] [Related]
51. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
52. Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation?
Linsley PS
J Exp Med; 1995 Aug; 182(2):289-92. PubMed ID: 7543133
[No Abstract] [Full Text] [Related]
53. Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4.
Cinek T; Sadra A; Imboden JB
J Immunol; 2000 Jan; 164(1):5-8. PubMed ID: 10604984
[TBL] [Abstract][Full Text] [Related]
54. The Yin and Yang of T cell costimulation.
Allison JP; Krummel MF
Science; 1995 Nov; 270(5238):932-3. PubMed ID: 7481795
[No Abstract] [Full Text] [Related]
55. Thyroid gland goes genomic. International Symposium: Genetics of Thyroid Disease, Munich, Germany, 4-5 September 1997.
Bennett ST; Schmutzler C
Trends Genet; 1997 Dec; 13(12):468. PubMed ID: 9433134
[No Abstract] [Full Text] [Related]
56. A native soluble form of CTLA-4.
Oaks MK; Hallett KM; Penwell RT; Stauber EC; Warren SJ; Tector AJ
Cell Immunol; 2000 May; 201(2):144-53. PubMed ID: 10831323
[TBL] [Abstract][Full Text] [Related]
57. Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
Yoo HY; Kim P; Kim WS; Lee SH; Kim S; Kang SY; Jang HY; Lee JE; Kim J; Kim SJ; Ko YH; Lee S
Haematologica; 2016 Jun; 101(6):e271. PubMed ID: 27252517
[No Abstract] [Full Text] [Related]
58. Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy.
Sfikakis PP; Via CS
Clin Immunol Immunopathol; 1997 Jun; 83(3):195-8. PubMed ID: 9175907
[No Abstract] [Full Text] [Related]
59. A chicken homologue of the co-stimulating molecule CD80 which binds to mammalian CTLA-4.
O'Regan MN; Parsons KR; Tregaskes CA; Young JR
Immunogenetics; 1999 Jan; 49(1):68-71. PubMed ID: 9811970
[No Abstract] [Full Text] [Related]
60. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep.
Drew DR; Boyle JS; Lew AM; Lightowlers MW; Chaplin PJ; Strugnell RA
Vaccine; 2001 Aug; 19(31):4417-28. PubMed ID: 11483267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
